Opus Genetics, Inc. Common Stock

IRD · Pharmaceutical Preparations · $431.0M
Powering up
IRD
$5.18
▼ −1.89%
09/18 O 5.29 H 5.34 L 5.11 C 5.18 ▼ −1.89%
Vol 5.5M RS 96
RS rating96
Now vs pivot (%)−2.26%
Tightening (ATR ratio)1.21×
Volume dry-up2.21×
Up/down volume, net0.39
From 52-week high27%
squatfailed pokeplayed out
Previous breakout stopped out ▼ −11.03% in Jan
Powering up
Moving averages
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

All four are in order, fastest above slowest — every timeframe pointing the same way.

The read

The base has run 4.2 weeks and fell 20% from its ceiling at its deepest. The pivot is $5.30, and the stock closed 2.3% below it. Its relative strength rating is 96.

Also on
Peers
Catalyst roadmap
  1. EarningstentativeLLY · competitorin 41d
    LLY reports
    Oct 29, 2026
  2. Earningstentativein 54d
    Quarterly earnings
    Nov 11, 2026
Flagged by the market sweep
GappedTape · 2026-09-17
-7.0%
New 52-week highTape · 2026-09-11
2.2x vol
GappedTape · 2026-09-11
+5.9%

From a separate overnight market sweep, not from the screens on this site. What it flagged, not what it means.

In the news
Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology ConferencesGlobeNewswire Inc. · 2026-09-02

Headlines link to the publisher. We do not host, summarise or rank them, and a headline appearing here is not a view about the company.

Insiders

No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.

X-ray

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. Historical figures are backtests and are hypothetical.

What that means, in full
Opus Genetics, Inc. Common Stock (IRD) — The Tape